2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (1ÀÏÂ÷) : 2022-10-15±³À°ÀÏÀÚ : 2022-10-15
±³À°Àå¼Ò : ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï ÄÚ¿¢½º Çϸð´Ïº¼·ë ¿Ü
±³À°ÁÖÁ¦ :
2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ´ëÇÑÇǺΰúÇÐȸ
¿¬¶ôó : 02-3473-0284
À̸ÞÀÏ :
kda@derma.or.kr ±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 19 ½Ã°£ 19ºÐ
¼¼ºÎ¼ö°·á : 500,000¿ø
ºñ°í Á¤È¸¿ø 80,000 / ÁØȸ¿ø 40,000 / ºñȸ¿ø 500,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10-15 Harmony 1+2 08:00~08:03 1. Introduction Chair()
±³À°½Ã°£ 10-15 Harmony 1+2 08:03~08:48 2. Real world evidence of biologics for PsO and clinical experience Dr. Melinda Gooderham(Skin health Canada)
Åä·Ð 10-15 Harmony 1+2 08:48~09:00 3. Q&A ()
±³À°½Ã°£ 10-15 Vivace 09:00~09:12 1. The effect of particulate matter in Demodex-induced immunomodulation of skin ±èÁöÈñ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 09:12~09:24 2. The role of tumor suppressor gene WWOX in skin inflammation via PKC and NF-kB signaling pathway ±èÁ¤Àº(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 09:24~09:36 3. A study on the effect of particulate matter on acne ¹Ú±Í¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 09:36~09:48 4. Investigation of the association between dermatologic disorders and the first exposure to general anesthesia using istrative healthcare databases ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 09:48~10:00 5. Establishment of vitiligo mouse model using transgenic mouse ÃÖÁ¾¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 Allegro 08:30~08:45 Overview and introduction of board exam Examination Committee()
±³À°½Ã°£ 10-15 Allegro 08:45~09:10 1. Keratinization, barrier development and skin immune system ½ÅÇöÅÂ(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 10-15 Allegro 09:10~09:35 2. Atopic dermatitis, contact dermatitis, seborrheic dermatitis, and other eczematous dermatitis ½Å±âÇõ(ºÎ»êÀÇ´ë)
ÈÞ½Ä 10-15 Allegro 09:35~09:40 Break ()
±³À°½Ã°£ 10-15 Allegro 09:40~10:05 3. Bacterial and fungal infection ¼Çö¹Î(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10-15 Allegro 10:05~10:25 4. Viral and other infection Áֹμ÷(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10-15 Allegro 10:25~10:45 5. Dermatopathology ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 10-15 Allegro 10:45~10:50 Break ()
±³À°½Ã°£ 10-15 Allegro 10:50~11:15 6. Papulosquamous disease ±èűÕ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-15 Allegro 11:15~11:30 7. Mucosal and adnexal disease Á¤ÀÇÇö(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 10:00~10:25 1. Non-dermatological itching exacerbated by scratching ±èÇý¿ø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 10:25~10:50 2. A look into the skin microbiome in chronic scratch lesions ±èÇý¼º(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 10:50~11:15 3. Journey with the expert researchers into melanocyte biology and pigmentary diseases À̽ÃÇü(¼¿ïÀÇ´ë)
Åä·Ð 10-15 Vivace 11:15~11:30 4. Q&A ()
±âŸ 10-15 Harmony 3 10:30~10:35 1. Introduction Chair()
±³À°½Ã°£ 10-15 Harmony 3 10:35~10:55 2-1. Atopic dermatitis: A personal disease with individual needs ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø)
±³À°½Ã°£ 10-15 Harmony 3 10:55~11:15 2-2. Addressing individual needs and tailored approaches to the treatment of patients with AD ³ªÂùÈ£(Á¶¼±ÀÇ´ë)
Åä·Ð 10-15 Harmony 3 11:15~11:30 3. Q&A ()
±³À°½Ã°£ 10-15 Allegro 14:00~14:05 1. Introduction Chair()
±³À°½Ã°£ 10-15 Allegro 14:05~14:25 2-1. Time to be LiMMitless: The SKY is the limit for psoriasis treatment Á¶¼ºÁø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 Allegro 14:25~14:45 2-2. Time to be obJAKtive: JAKi °íÇöâ(ºÎ»êÀÇ´ë)
Åä·Ð 10-15 Allegro 14:45~15:00 3. Q&A ()
±³À°½Ã°£ 10-15 Harmony 1+2 11:30~11:33 1. Introduction Chair()
±³À°½Ã°£ 10-15 Harmony 1+2 11:33~12:18 2. Drug survival associated with effectiveness and safety of treatment with guselkumab Alexander Egeberg(Copenhagen University Hospital Denmark)
Åä·Ð 10-15 Harmony 1+2 12:18~12:30 3. Q&A ()
±âŸ 10-15 Harmony 1+2 13:10~13:15 1. Introduction ±èÀ¯Âù(´ëÇÑÇǺΰúÇÐȸ ȸÀå)
±³À°½Ã°£ 10-15 Harmony 1+2 13:15~13:30 2. Herpes zoster ÀÌÁøŹ(ÀÌÁøŹÇǺΰú)
±âŸ 10-15 Harmony 1+2 13:30~13:35 1. Introduction ()
±³À°½Ã°£ 10-15 Harmony 1+2 13:35~13:55 2. First metastasis of acral melanoma: Role of pigmentation À±¼÷Á¤(Àü³²ÀÇ´ë)
Åä·Ð 10-15 Harmony 1+2 13:55~14:00 3. Q&A ()
±³À°½Ã°£ 10-15 Harmony 1+2 14:00~14:50 1. Alopecia areata updates ½É¿ì¿µ(°æÈñÀÇ´ë)
Åä·Ð 10-15 Harmony 1+2 14:50~15:00 2. Q&A ()
±âŸ 10-15 Harmony 3 14:00~14:03 1. Overview Chair()
±³À°½Ã°£ 10-15 Harmony 3 14:03~14:15 2. Physical signs of the nail unit Á¤ÇýÁ¤(±¹¸³Áß¾ÓÀÇ·á¿ø)
±³À°½Ã°£ 10-15 Harmony 3 14:15~14:27 3. Nail changes by contact materials À̽ÂÈ£(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 14:27~14:39 4. Non-melanocytic tumors of the nail unit ¹®Á¦È£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 14:39~14:51 5. Nail biopsy ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë)
Åä·Ð 10-15 Harmony 3 14:51~15:00 6. Q&A ()
±³À°½Ã°£ 10-15 Harmony 3 15:30~15:35 1. Overview Chair()
±³À°½Ã°£ 10-15 Harmony 3 15:35~15:50 2. Introduction to hair biology ¹ÚÇö¼±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 15:50~16:05 3. Molecular dissection of hair structures with single cell sequencing ±èµµ¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 16:05~16:20 4. Genetic prediction of alopecia ½ÅÇöÅÂ(ÀÎÇÏÀÇ´ë)
Åä·Ð 10-15 Harmony 3 16:20~16:30 5. Q&A ()
±³À°½Ã°£ 10-15 Vivace 14:00~14:17 1. Confusing skin disease: MF, CTCL vs. Atopic dermatitis ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø)
±³À°½Ã°£ 10-15 Vivace 14:17~14:34 2. Challenging clinical cases: Not an easy one ÀÌ¿ìÁø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 14:34~14:51 3. Selection of interesting or educative cases CME ÀÌÁöÇý(°¡Å縯ÀÇ´ë)
Åä·Ð 10-15 Vivace 14:51~15:00 4. Q&A ()
±³À°½Ã°£ 10-15 Vivace 15:30~15:47 1. Pathogenesis À强Àº(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 15:47~16:04 2. Assessment of high-risk patients for PIH ³ªÁ¤ÀÓ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 16:04~16:21 3. Prevention & treatment ±èÁ¤Àº(ÇѾçÀÇ´ë)
Åä·Ð 10-15 Vivace 16:21~16:30 4. Q&A ()
±³À°½Ã°£ 10-15 Vivace 16:30~16:47 1. Chronic inflammatory dermatosis ±èÇöÁ¤(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 16:47~17:04 2. Acne and rosacea Á¶¼Ò¿¬(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 Vivace 17:04~17:21 3. Aging skin ÃÖÀÀÈ£(¿¬¼¼¿øÁÖÀÇ´ë)
Åä·Ð 10-15 Vivace 17:21~17:30 4. Q&A ()
±³À°½Ã°£ 10-15 Harmony 1+2 15:30~15:35 1. Introduction Chair()
±³À°½Ã°£ 10-15 Harmony 1+2 15:35~16:20 2. How did ex-Hansen patients survive in modern Korea: Visiting and recording sites related to ex-Hansen patients ±è½Ã´ö(¹®ÇåÇÐÀÚ)
Åä·Ð 10-15 Harmony 1+2 16:20~16:30 3. Q&A ()
±³À°½Ã°£ 10-15 Harmony 1+2 16:30~16:42 1. The role of IL-17 in the pathogenesis of PsO & PsA Á¤±âÇå(°æÈñÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 1+2 16:42~16:54 2. IL-17 blocker: Secukinumab ±èűÕ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 1+2 16:54~17:06 3. IL-17 blocker: Ixekizumab ¹æöȯ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 1+2 17:06~17:18 4. IL-17 blocker: Others (brodalumab, bimekizumab) ¹éÀ¯»ó(°í·ÁÀÇ´ë)
Åä·Ð 10-15 Harmony 1+2 17:18~17:30 5. Q&A ()
±³À°½Ã°£ 10-15 Harmony 3 16:30~16:40 1. A 94-year-old woman with a rapidly growing erythematous tumor on the right cheek ±èµ¿Çö(Â÷ÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 16:40~16:50 2. Hyperkeratotic erythematous plaque on the right temple in a 76-year-old man ÇÏ´ë·æ(°æºÏÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 16:50~17:00 3. Indurated, ill-defined patches with telangiectasia on both thighs in a 51-year-old female patient ÀÌ¿ìÁø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 17:00~17:10 4. Progressively enlarging erythematous-to-brownish sclerotic plaque on the back ¹®Á¦È£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 17:10~17:20 5. Multiple variable sized hard painful erythematous nodules and pustules on trunk and extremities Ãֹ̼ö(´Ü±¹ÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 17:20~17:30 6. Grouped annular erythematous eruption with vesicles and pustules on the trunk on a 27-year-old male ±èÁöÈñ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 17:30~17:40 7. A firm lump on the flank of a 6-year-old boy ¹ÚÁöÇì(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-15 Harmony 3 17:40~17:50 8. Asymptomatic diffuse brownish to black patches and tumors in a 57-year-old woman À±¼÷Á¤(Àü³²ÀÇ´ë)
Åä·Ð 10-15 Harmony 3 17:50~18:00 9. Q&A ()